NASDAQ: DOMHDominari Holdings Inc Stock
$3.36+0.11 (+3.38%)
Updated Mar 24, 2023
DOMH Price
$3.36
Fair Value Price
$9.81
Market Cap
$18.43M
52 Week Low
$2.88
52 Week High
$10.20
P/E
-0.87x
P/B
0.23x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$16.66M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$11M
Beta
-0.1
Next Earnings
Mar 27, 2023
Ex-Dividend
N/A
Next Dividend
N/A
DOMH Overview
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DOMH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DOMH ($3.36) is undervalued by 65.76% relative to our estimate of its Fair Value price of $9.81 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
DOMH ($3.36) is significantly undervalued by 65.76% relative to our estimate of its Fair Value price of $9.81 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
DOMH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DOMH due diligence checks available for Premium users.
Be the first to know about important DOMH news, forecast changes, insider trades & much more!
DOMH News
Valuation
DOMH fair value
Fair Value of DOMH stock based on Discounted Cash Flow (DCF)
Price
$3.36
Fair Value
$9.81
Undervalued by
65.76%
DOMH ($3.36) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DOMH ($3.36) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DOMH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DOMH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.87x
Industry
17.88x
Market
21.37x
DOMH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.23x
Industry
4.89x
DOMH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DOMH's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.2M
Profit Margin
0%
DOMH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$84.4M
Liabilities
$2.6M
Debt to equity
0.03
DOMH's short-term assets ($56.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DOMH's short-term assets ($56.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DOMH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DOMH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
-$681.0k
Financing
-$751.0k
DOMH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DOMH vs Biotech Stocks
Dominari Holdings Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.